8-K: Liminatus Pharma Awaits Nasdaq Compliance Decision

Liminatus Pharma, Inc. reports stockholder equity exceeding $2.5 million post-merger, awaiting Nasdaq's compliance determination while acknowledging ongoing monitoring.

Summary

• Liminatus Pharma, Inc. has announced that as of July 29, 2026, its stockholder equity is believed to exceed $2.5 million following a merger with InnocsAI LLC.
• The company is currently awaiting a compliance determination from The Nasdaq Stock Market LLC (Nasdaq).
• Nasdaq will continue to monitor the company's ongoing compliance with stockholder equity requirements.
• Failure to demonstrate compliance in future periodic reports could subject the company to delisting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the pending Nasdaq compliance determination and the inherent risk of delisting, despite the reported increase in stockholder equity.

Positives

• Stockholder equity is reported to be in excess of $2.5 million as of July 29, 2026, following the merger with InnocsAI LLC.

Negatives

• The company is awaiting a compliance determination from Nasdaq regarding its stockholder equity.
• There is a risk of future delisting if the company does not evidence ongoing compliance with Nasdaq's rules in future periodic reports.

Risks

• There can be no assurance that Nasdaq will accept the company's plan to regain compliance.
• There is no guarantee that the company will regain compliance with Nasdaq listing rules during any compliance period or in the future.
• The company may not meet Nasdaq's continued listing standards.
• Actual actions or events could differ materially from forward-looking statements.

Future Outlook

The company is awaiting a compliance determination from Nasdaq and will be subject to ongoing monitoring. Future compliance with Nasdaq's continued listing standards is uncertain and could lead to delisting if not met.

Management Comments

• As a result of the previously announced merger transaction with InnocsAI LLC, as of the date of this Current Report on Form 8-K, Liminatus Pharma, Inc. (the Company) believes it has stockholders equity in excess of $2.5 million.

Industry Context

StockSavvy.ai notes that maintaining listing on major exchanges like Nasdaq is critical for pharmaceutical companies seeking access to capital and investor confidence. Compliance issues, especially post-merger, can create significant uncertainty.

Stakeholder Impact

• Shareholders: Potential delisting could negatively impact share liquidity and valuation.
• Investors: Uncertainty surrounding Nasdaq compliance may deter new investment.

Next Steps

• Await compliance determination from The Nasdaq Stock Market LLC.
• Continue to monitor ongoing compliance with stockholder equity requirements.
• Demonstrate compliance in the next periodic report to avoid potential delisting.

Key Dates

Recommendation

The recommendation is 'hold' due to the uncertainty surrounding Nasdaq compliance. While the company has reported an increase in stockholder equity post-merger, the pending determination and the risk of delisting warrant a cautious approach. Investors should monitor the Nasdaq decision and the company's subsequent compliance efforts.

Keywords

Liminatus Pharma, InnocsAI LLC, Nasdaq compliance, stockholder equity, merger, delisting risk